What do you mean my new smart scale is ‘built for GLP-1 users’?
Withings is marketing a smart scale for GLP-1 users, but the claim feels broader than the hardware itself. The piece sees this as a sign health tech is racing to adapt to GLP-1 treatments.
Intelligence analysis by GPT-5.4 Mini
The article opens with a Withings smart scale pitched as “built for GLP-1 users” and argues that the fit is real but overstated. It uses that example to show how health tech companies are starting to chase the growing GLP-1 market with more metabolic tracking features.
A smart scale is being sold like it was made for people taking certain weight-loss medicines. The article says that makes some sense, but it is mostly the same scale with a new label, like putting a new sticker on a backpack.
Analysis
A GLP-1 pitch on a smart scale
Victoria Song describes a product launch for the Withings BodyFit, a smart scale marketed as “built for GLP-1 users.” The scale is positioned as a lower-cost, wellness-focused version of Withings’ pricier Body Scan model, with segmented body composition analysis via a retractable handle, but without some of the more medically oriented features.
The article’s core argument is that the GLP-1 angle is not entirely wrong, but it is also not especially specific. GLP-1 drugs such as Ozempic, Wegovy, Zepbound, and Mounjaro can suppress appetite and slow digestion, and one concern for users is losing muscle along with weight. That is why doctors often advise people on these medications to prioritize protein and strength training. A scale that tracks body composition can help monitor muscle mass, so the product has a plausible use case. Still, the piece argues that this is an existing health device being repackaged with a new label.
Broader trend in health tech
Song frames this as part of a larger shift in wearable and metabolic health products. Withings’ vice president of health solutions, Antoine Pivron, says GLP-1 therapies changed obesity care but did not remove the need for long-term support, and that the company sees a move toward more personalized, connected metabolic care.
The article also points to Oura, which recently announced “GLP-1 insights” in its app. That makes the author’s point sharper: major health tech brands are likely to lean harder into GLP-1 branding because a large share of Americans have used or are using these medications. The piece is skeptical of the marketing, but it treats the direction of travel as real.
Why the skepticism
Song writes from personal experience as someone on a GLP-1 medication, saying the side effects and adjustment period have been difficult. That gives the criticism weight: existing wearables and AI health tools often assume a fairly average user, while people with unusual medication experiences may need more nuanced support. The article suggests that logging symptoms is easy enough; the harder part is turning that data into useful patterns and doctor-ready insight.
Key points
- Withings is marketing the BodyFit smart scale as “built for GLP-1 users.”
- The article argues the scale is useful, but the GLP-1 framing is broader than the hardware itself.
- GLP-1 medications can lead some users to lose muscle, which makes body-composition tracking relevant.
- The piece says health tech companies are likely to push more GLP-1-focused features and marketing.
- The author is skeptical of the hype because many wearables still work from a generic, average-user model.
If these products improve, people taking GLP-1 medications could get better tracking of muscle loss and other body changes. That could make it easier to pair medication with protein intake, strength training, and more informed doctor visits.
The downside is that companies may overmarket ordinary health gadgets as specialized tools without solving the real problem. If the apps still treat users like a generic average person, they may collect data without helping people understand what to do next.
